Kura Oncology (KURA) Non Operating Income (2014 - 2026)
Kura Oncology (KURA) reported Non Operating Income of $5.5 million for Q1 2026, down 26.77% year-over-year from $7.5 million in Q1 2025, and down 26.77% on a QoQ basis from $7.5 million in Q1 2025.
Kura Oncology (KURA) has 13 years of Non Operating Income data on file, last reported at $5.5 million in Q1 2026.
- Quarterly Non Operating Income fell 26.77% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.7 million (changed 0.32% YoY) and the FY2025 annual result came in at $25.3 million, up 18.99% from the prior year.
- Non Operating Income slipped to $5.5 million in Q1 2026 per KURA's latest filing, from $7.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $7.5 million in Q1 2025 and bottomed at $329000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $3.9 million (2023), against an average of $3.7 million.
- The widest annual swing landed in 2022, when Non Operating Income surged 3625.0%; it then fell 26.77% in 2026.
- Tracing KURA's Non Operating Income over 5 years: stood at $2.0 million in 2022, then surged by 94.71% to $4.0 million in 2023, then surged by 32.19% to $5.3 million in 2024, then jumped by 42.64% to $7.5 million in 2025, then slipped by 26.77% to $5.5 million in 2026.
- Per Business Quant, the three latest KURA Non Operating Income figures stand at $5.5 million (Q1 2026), $7.5 million (Q1 2025), and $5.3 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 5.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.49 Mn |
| Mar 31, 2025 | 7.50 Mn |
| Dec 31, 2024 | 5.26 Mn |
| Sep 30, 2024 | 5.48 Mn |
| Jun 30, 2024 | 5.57 Mn |
| Mar 31, 2024 | 4.93 Mn |
| Dec 31, 2023 | 3.98 Mn |
| Sep 30, 2023 | 3.87 Mn |
| Jun 30, 2023 | 2.83 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.04 Mn |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 564,000.00 |
| Mar 31, 2022 | 329,000.00 |
| Dec 31, 2021 | 295,000.00 |
| Sep 30, 2021 | 311,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | 202,000.00 |
| Dec 31, 2020 | 173,000.00 |
| Sep 30, 2020 | 425,000.00 |
| Jun 30, 2020 | 686,000.00 |
| Mar 31, 2020 | 990,000.00 |
| Dec 31, 2019 | 1.10 Mn |
| Sep 30, 2019 | 1.28 Mn |
| Jun 30, 2019 | 948,000.00 |
| Mar 31, 2019 | 1.01 Mn |
| Dec 31, 2018 | 537,000.00 |
| Sep 30, 2018 | 975,000.00 |
| Jun 30, 2018 | 537,000.00 |
| Mar 31, 2018 | 387,000.00 |
| Dec 31, 2017 | 247,000.00 |
| Sep 30, 2017 | 166,000.00 |
| Jun 30, 2017 | 110,000.00 |
| Mar 31, 2017 | 120,000.00 |
| Dec 31, 2016 | 131,000.00 |
| Sep 30, 2016 | 132,000.00 |
| Jun 30, 2016 | 130,000.00 |
| Mar 31, 2016 | 414,000.00 |
| Dec 31, 2015 | 368,000.00 |
| Sep 30, 2015 | 338,000.00 |
| Jun 30, 2015 | 322,000.00 |
| Mar 31, 2015 | 212,000.00 |
| Dec 31, 2014 | 263,000.00 |